<!DOCTYPE html>
<html lang="en"
>
<head>
    <title>Infinite regress</title>
    <!-- Using the latest rendering mode for IE -->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">



<link rel="canonical" href="http://miljko.org">
        <meta name="author" content="Miloš Miljković" />

    <!-- Enable latex plugin -->


    <!-- Open Graph tags -->
        <meta property="og:site_name" content="Infinite regress" />
        <meta property="og:type" content="website"/>
        <meta property="og:title" content="Infinite regress"/>
        <meta property="og:url" content="http://miljko.org"/>
        <meta property="og:description" content="Infinite regress"/>

    <meta name="twitter:card" content="summary">
        <meta name="twitter:site" content="@miljko">
        <meta name="twitter:creator" content="@miljko">
    <meta name="twitter:domain" content="http://miljko.org">

    <!-- Bootstrap -->
        <link rel="stylesheet" href="http://miljko.org/theme/css/bootstrap.aplan.min.css" type="text/css"/>
    <link href="http://miljko.org/theme/css/font-awesome.min.css" rel="stylesheet">

    <link href="http://miljko.org/theme/css/pygments/native.css" rel="stylesheet">
        <link href="http://miljko.org/theme/css/typogrify.css" rel="stylesheet">
    <link rel="stylesheet" href="http://miljko.org/theme/css/style.css" type="text/css"/>

        <link href="http://miljko.org/rss/index.xml" type="application/rss+xml" rel="alternate"
              title="Infinite regress RSS Feed"/>


    <style type="text/css">
    p {
        margin-top: 18px;
        margin-bottom: 18px;
    }
    </style>

</head>
<body>

<div class="navbar navbar-default navbar-fixed-top" role="navigation">
    <div class="container">
        <div class="navbar-header">
            <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-ex1-collapse">
                <span class="sr-only">Toggle navigation</span>
                <span class="icon-bar"></span>
                <span class="icon-bar"></span>
                <span class="icon-bar"></span>
            </button>
            <a href="http://miljko.org/" class="navbar-brand">
Infinite regress            </a>
        </div>
        <div class="collapse navbar-collapse navbar-ex1-collapse">
            <ul class="nav navbar-nav">
                        <li >
                            <a href="http://miljko.org/category/blog.html">Blog</a>
                        </li>
                        <li >
                            <a href="http://miljko.org/category/pisanije.html">Pisanije</a>
                        </li>
                        <li >
                            <a href="http://miljko.org/category/reviews.html">Reviews</a>
                        </li>
            </ul>
            <ul class="nav navbar-nav navbar-right">
                <li><a href="http://miljko.org/archives.html"><i class="fa fa-th-list"></i><span class="icon-label">Archives</span></a></li>
            </ul>
        </div>
        <!-- /.navbar-collapse -->
    </div>
</div> <!-- /.navbar -->

<div class="container">
    <div class="row">
        <div class="col-lg-12">

            <article>
                <h2><a href="http://miljko.org/srb/2015/04/28/vanredno-stanje/">Vanredno&nbsp;stanje</a></h2>
                <div class="summary"><p>Moj frizer, Amerikanac grčkog porekla, je nakon očeve smrti proveo mesec
dana u Atini da bi prodao stan—neplanirano, pošto nije znao da je Grčka
zatvorena u avgustu. Para imao nije, pa je vreme provodio gledajući
grčku televiziju (&#8220;6 glava preko celog ekrana, viču jedna na drugu&#8221;) i
razgovarajući sa ujakom i njegovim prijateljima, uglavnom o prljavim,
pokvarenim, lenjim&nbsp;Albancima.</p>
<p>Utisak: ljudi su svuda isti. Svako ima svoje crnce i Meksikance, i svoj
<span class="caps">FOX</span>&nbsp;News.</p>
<p>Juče su grupe siromašne omladine sa viškom vremena i manjkom
ciljeva—možda a možda i ne podstaknute vrhom baltimorske sive i crne
ekonomije—lomile, palile, i krale po svom gradu. Policija je bacala
suzavac, omladina je bacala cigle. <a href="http://www.baltimoresun.com/news/maryland/baltimore-city/bs-md-ci-freddie-gray-viewing-20150426-story.html">Razlog za demonstracije</a>
brzo su zaboravili i demonstranti, i policija, <a href="http://mic.com/articles/116524/outrage-over-baltimore-riots-completely-misses-the-point">a pre svih
novinari</a>.</p>
<p>Da nisam na odmoru, bio bih iznerviran jer je deo grada kojim svakog
jutra idem na posao bio u haosu. Kao što je 23-ojka koja me je vozila od
Karaburme do Instituta za histologiju stajala dok su palili ambasade u
Kneza&nbsp;Miloša.</p>
<p>Ljudi su svuda isti, osim kad&nbsp;nisu.</p>
<p>Naša zalutala omladina voli da pali, lomi, i pljačka centar grada.
Baltimorska uništava sopstveni, već propali komšiluk. Naša se nominalno
bori za Kosovo (ili, izgleda, za istrebljenje suparničkog tima),
baltimorska protiv policijske brutalnosti. Situacija u Baltimoru je
jasna: narko preduzetnici sa jedne strane, policija sa druge, siromašni
crnci kao pijuni u sredini. Ko se drži po strani popije zalutali metak, suzavac,
lom vratnog pršljena. U Srbiji se teže razaznaje ko koga napada,
podržava, podstiče, i brani. Ne znam šta je bolje, i ne znam za&nbsp;koga.</p>
<p>Pretpostaviću da ste kao svaki dobar akademski građanin odgledali <a href="http://en.wikipedia.org/wiki/The_Wire">The
Wire</a>. Dejvid Sajmon je <a href="http://davidsimon.com/">na svom blogu</a> već ranije pisao
kako je čudo što do bacanja cigli nije došlo ranije, i u većoj meri.
Neki su u komentarima to protumačili kao podrška jučerašnjim protestima.
U <a href="http://davidsimon.com/baltimore/">svom poslednjem tekstu</a> je zamolio ljude da prestanu sa
paljenjem, i da se vrate kući. Neki drugi su u tome videli bogatog belca
koji crncima naređuje da&nbsp;ćute.</p>
<p>Sviđa mi se kako Sajmon razmišlja, a i napravio je odličnu seriju,
pa ću reći da je u pravu čim ga napadaju obe strane. To nije neki
argument, ali i pored skoro pet godina provedenih u Baltimoru, bolji
nemam—razmišljao sam o drugim stvarima. Ako vas interesuju rasne borbe
i rat protiv droge u Americi, a imate par sati, pročitajte Sajmonove
stare članke i <a href="https://www.youtube.com/watch?v=xWY79JCfhjw">odgledajte ovo</a>. Ja vam neću uzimati više&nbsp;vremena.</p>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/srb/2015/04/28/vanredno-stanje/">more ...</a>
                </div>
            </article>
            <hr/>
            <article>
                <h2><a href="http://miljko.org/eng/2015/04/25/kaposis-not-your-every-day-sarcoma/">Kaposi’s: not your every day&nbsp;sarcoma</a></h2>
                <div class="summary"><p>Kaposi&#8217;s sarcoma is an often misunderstood disease. You don&#8217;t need to have <span class="caps">AIDS</span> to get it; if it is <span class="caps">AIDS</span>-associated it doesn&#8217;t always disappear with antiretroviral therapy; and if it does it may come back years later. Even oncologists in the <span class="caps">US</span> don&#8217;t see it often, let alone podiatrists—hence some bizare treatment recommendations in the slides&nbsp;below.</p>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/eng/2015/04/25/kaposis-not-your-every-day-sarcoma/">more ...</a>
                </div>
            </article>
            <hr/>
            <article>
                <h2><a href="http://miljko.org/eng/2015/04/11/ultrasubspecialization/">The pitfalls of&nbsp;ultrasubspecialization</a></h2>
                <div class="summary"><p>If you haven&#8217;t yet seen <a href="http://cancerfilms.org/">the new <span class="caps">PBS</span> documentary on Cancer</a>, do it as
soon as possible. A free stream is available <a href="http://video.pbs.org/program/story-cancer-emperor-all-maladies/">on the <span class="caps">PBS</span> website</a>
but it is well worth the $15 on&nbsp;iTunes.</p>
<p>It makes many good points, one of which is the siliness of viewing
cancer in general, or of any particular organ, as being a single
entity. Genitourinary and <span class="caps">GYN</span> malignancies are sill fresh in my
mind after this last rotation, so an example that comes first is
prostate cancer. Most have your standard testosterone-dependent, androgen
deprivation therapy-sensitive cells. Once they stop responding to
hormonal therapy, treatment is still targeted towards the (now mutated)
androgen receptor. Small cell prostate cancer, however, looks and
behaves differently—tending to be bulkier, more aggressive, and having
earlier visceral organ metastases. Ultimately, we treat it more like its
namesake in the lung, with cisplatin and&nbsp;etoposide.</p>
<p>That was an easy distinction to make, since small cell prostate cancer
looks nothing like adenocarcinoma under a microscope. Not so for
breast cancer. We now know that it is at least four diseases which are
at first glance all the same: luminal A (hormone receptor-positive,
Her2-negaitve); luminal B (<span class="caps">HR</span>-positive, Her2-positive); <span class="caps">HR</span>-negative,
Her2-positive; and triple-negative (also called basal-like, though
definitions of basal-like breast cancer vary). The first three, which
we are now able to distinguish with immunohistochemistry and <span class="caps">FISH</span>,
have different behaviour, treatment, and prognosis. The fourth is
a catch-all category that probably contains many different diseases we
don&#8217;t know about yet. Some of those triple-negatives may have more in
common with colon or lung cancer than they do with other malignancies of
the&nbsp;breast.</p>
<p>Which organ the cancer is in should be important to a surgeon or a
radiation oncologist, who have to deal with the anatomy. But should
medical oncologists subspecialize by organ, or by cell? Why is a
neuro-oncologist better suited to treat primary <span class="caps">CNS</span> lymphoma than
a hematologist whose main interest are aggresive lymphomas? Does a
<span class="caps">GI</span> oncologist have a better skillset and knowledge base for dealing
with neuroendocrine tumors of the pancreas than an oncologist who
deals with endocrine gland malignancies? Are there other, not so obvious
connections between different cancers that we are missing because of&nbsp;ultrasubspecialization?</p>
<p>I don&#8217;t know enough oncology to answer any of these questions, but they
are interesting questions to&nbsp;make.</p>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/eng/2015/04/11/ultrasubspecialization/">more ...</a>
                </div>
            </article>
            <hr/>
            <article>
                <h2><a href="http://miljko.org/eng/2015/03/24/male-breast-cancer-designing-a-trial/">Male breast cancer: designing a&nbsp;trial</a></h2>
                <div class="summary"><p>Shortly after [posting my latest tumor board presentation][cmc8], I discovered that someone is making a documentary about men with breast cancer. The preview looked&nbsp;interesting.</p>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/eng/2015/03/24/male-breast-cancer-designing-a-trial/">more ...</a>
                </div>
            </article>
            <hr/>
            <article>
                <h2><a href="http://miljko.org/eng/2015/03/22/male-breast-cancer-a-slide-show/">Male breast cancer, a slide&nbsp;show</a></h2>
                <div class="summary"><p>As the year winds down, these tumor board presentations will get less frequent.  For now, though, it is still once a month. My latest, on breast cancer in men, seemed to be well-received. I suspect it was because, unlike most rare cancers, this one was easy to fit into a preexisting pattern: it is just like female breast cancer, except for… And voilà—you get quick and easily understood knowledge about a whole new disease&nbsp;entity.</p>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/eng/2015/03/22/male-breast-cancer-a-slide-show/">more ...</a>
                </div>
            </article>
            <hr/>
            <article>
                <h2><a href="http://miljko.org/eng/2015/02/28/dosegate/">Apple’s App Store rules, Dosegate&nbsp;edition</a></h2>
                <div class="summary"><p>First they came for the <a href="http://mjtsai.com/blog/2014/06/08/editorial-1-1-1-rejected-from-the-app-store/">nerds</a>.</p>
<p>Now they are <a href="https://itunes.apple.com/app/id806809930?at=1l3v3Zp">coming for the doctors</a> (see What&#8217;s New in Version 3.0.5).
The makers of MedCalc, the best medical calculator app out there, <a href="http://medcalc.medserver.be/dosegate.html">explained
what happend</a> in detail<sup id="fnref:dosegate"><a class="footnote-ref" href="#fn:dosegate" rel="footnote">1</a></sup>. This was the rule they were
supposedly&nbsp;infringing:</p>
<blockquote>
<p><strong>22.9</strong> Apps that calculate medicinal dosages must be submitted by the
manufacturer of those medications or recognized institutions such as
hospitals, insurance companies, and&nbsp;universities.</p>
</blockquote>
<p>Nevermind that many doctors view themselves as institutions—this is
an idiotic rule. Is University of Baltimore, which has no biomedical
science courses or programs, allowed to publish a drug dose calculator?
Is <span class="caps">GEICO</span>?</p>
<p>The <span class="caps">FDA</span> has issued <a href="http://www.fda.gov/downloads/MedicalDevices/.../UCM263366.pdf">guidance for mobile medical apps</a>. It
specificaly allows calculators that use generally available formulas,
and forbids apps which calculate <em>radiation</em> dosage, but does not
mention drugs. Where, then, did this rule come&nbsp;from?</p>
<p>It is, of course, the same App store rules that allowed <a href="https://itunes.apple.com/us/app/homeopathy-cures/id479869465?mt=8">these</a> <a href="https://itunes.apple.com/us/app/homeopathy-materia-medica/id623045549?mt=8">pearls</a>
of <a href="https://itunes.apple.com/us/app/kent-homeopathic-repertory/id681045237?mt=8">quackery</a>.</p>
<p>It&#8217;s madness, and it&#8217;s&nbsp;maddening.</p>
<div class="footnote">
<hr>
<ol>
<li id="fn:dosegate">
<p>Seeing that <span class="caps">URL</span> made me appreciate the developers even more.&#160;<a class="footnote-backref" href="#fnref:dosegate" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a></p>
</li>
</ol>
</div>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/eng/2015/02/28/dosegate/">more ...</a>
                </div>
            </article>
            <hr/>
            <article>
                <h2><a href="http://miljko.org/eng/2015/02/26/opasnosti-vrebaju/">Opasnosti&nbsp;vrebaju</a></h2>
                <div class="summary"><p>Pacijent u ordinaciji ima pedesetak godina, izgleda mlađe. Oćelaveo od terapije, mada bih po konstituciji, odeći, i stavu—dva metra i mišićav, tri krsta i brojanica, vojnički i za dva decibila preglasan—pretpostavio da nikada nije imao bujne&nbsp;lokne.</p>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/eng/2015/02/26/opasnosti-vrebaju/">more ...</a>
                </div>
            </article>
            <hr/>
            <article>
                <h2><a href="http://miljko.org/eng/2015/02/20/adjuvant-hormonal-therapy-in-early-stage-breast-cancer/">Adjuvant hormonal therapy in early stage breast&nbsp;cancer</a></h2>
                <div class="summary"><p>The field of breast cancer research is nothing if not full of highly-powered, multicenter, seemingly decades-long trials. Which is good, since there are many questions that need&nbsp;answering.</p>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/eng/2015/02/20/adjuvant-hormonal-therapy-in-early-stage-breast-cancer/">more ...</a>
                </div>
            </article>
            <hr/>
            <article>
                <h2><a href="http://miljko.org/eng/2015/02/20/clinical-center-grand-rounds-moxetumomab-for-hairy-cell-leukemia/">Clinical Center Grand Rounds — Moxetumomab for hairy cell&nbsp;leukemia</a></h2>
                <div class="summary"><p>It was an honor to contribute to the <span class="caps">NIH</span> Clinical Center Grand Rounds this week—a straightforward presentation of a fascinating case, followed by the brilliant Drs. Kreitman and Pastan discussing the anti-<span class="caps">CD22</span> immunotoxin&nbsp;Moxetumomab.</p>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/eng/2015/02/20/clinical-center-grand-rounds-moxetumomab-for-hairy-cell-leukemia/">more ...</a>
                </div>
            </article>
            <hr/>
            <article>
                <h2><a href="http://miljko.org/eng/2015/02/19/the-more-you-know/">The more you&nbsp;know…</a></h2>
                <div class="summary"><p>If the unstated goal of these rotation post-mortems was to summarize
what I had learned, a single post may not be enough for breast
cancer. Six weeks ago, I knew that it was <a href="http://www.cancer.gov/cancertopics/factsheet/detection/probability-breast-cancer">common</a>, maybe
<a href="http://www.cancer.gov/cancertopics/pdq/screening/breast/HealthProfessional/page8#_423_toc">overdiagnosed</a>, possibly <a href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.28260/full">overtreated</a>,
and <a href="http://www.cancer.gov/cancertopics/factsheet/NCI/research-funding">beating all other cancers for research funding by a vast
margin</a>. All this was a vague sense of being informed—like a
<span class="caps">NYT</span> reader may feel after reading the Sunday Magazine feature—rather than
actual&nbsp;knowledge.</p>
<p>Having talked to a good number of women with breast cancer, and
worked with a few attendings dedicated to the field, I know it
enough to know that I need to know more; but also enough to
keep me interested. What from the outside looks like cookbook
<em>this-marker-means-she&#8217;s-getting-that-treatment</em> medicine is in fact an
intricate work of knowing your patient, figuring out where she stands in
the heaps of data generated by decades-long studies following thousands
of women on different protocols, discussing the options, and coming to a
mutualy agreed decision<sup id="fnref:preposterous"><a class="footnote-ref" href="#fn:preposterous" rel="footnote">1</a></sup>. Hard work, all of&nbsp;it.</p>
<p>Harder still is working on those data-generating trials. Anyone can
think of a clinicaly relevant question, but can they make it into a
feasable protocol? Can they gather a team to manage all the patients in
the center, and all the different centers? Can they manage that team?
<a href="http://www.cancer.gov/cancertopics/factsheet/NCI/research-funding">Looking at a recent set of trials you will hear more about soon</a>,
the scale boggles the&nbsp;mind.</p>
<p>Side note: &#8220;We don&#8217;t have a crystal ball&#8221; is common oncspeak for &#8220;I
don&#8217;t know what your prognosis is&#8221;<sup id="fnref:badprog"><a class="footnote-ref" href="#fn:badprog" rel="footnote">2</a></sup>, but if a person has breast
cancer what are <a href="http://www.cancer.gov/bcrisktool/">the Gail model</a> or <a href="http://www.oncotypedx.com/">Oncotype <span class="caps">DX</span></a> if not
(developing, imperfect) tellers of fortune? And wouldn&#8217;t it be great to
have a similar set of tools and statistics for all&nbsp;cancers?</p>
<p>So, not going into the field, but thoroughly&nbsp;impressed.</p>
<div class="footnote">
<hr>
<ol>
<li id="fn:preposterous">
<p>Which is—truth be told—what we should do for any cancer, or
illness. Alas, most diseases lack data, options, or both.&#160;<a class="footnote-backref" href="#fnref:preposterous" rev="footnote" title="Jump back to footnote 1 in the text">&#8617;</a></p>
</li>
<li id="fn:badprog">
<p>Or in the paternalistic dialect of the language, &#8220;I don&#8217;t want to tell you that you prognosis is poor&#8221;.&#160;<a class="footnote-backref" href="#fnref:badprog" rev="footnote" title="Jump back to footnote 2 in the text">&#8617;</a></p>
</li>
</ol>
</div>
                    <a class="btn btn-default btn-xs" href="http://miljko.org/eng/2015/02/19/the-more-you-know/">more ...</a>
                </div>
            </article>
            <hr/>

        <ul class="pagination">
                <li class="prev"><a href="http://miljko.org/index7.html">&laquo;</a>
                </li>
                    <li class=""><a
                            href="http://miljko.org/index.html">1</a></li>
                    <li class=""><a
                            href="http://miljko.org/index2.html">2</a></li>
                    <li class=""><a
                            href="http://miljko.org/index3.html">3</a></li>
                    <li class=""><a
                            href="http://miljko.org/index4.html">4</a></li>
                    <li class=""><a
                            href="http://miljko.org/index5.html">5</a></li>
                    <li class=""><a
                            href="http://miljko.org/index6.html">6</a></li>
                    <li class=""><a
                            href="http://miljko.org/index7.html">7</a></li>
                    <li class="active"><a
                            href="http://miljko.org/index8.html">8</a></li>
                    <li class=""><a
                            href="http://miljko.org/index9.html">9</a></li>
                    <li class=""><a
                            href="http://miljko.org/index10.html">10</a></li>
                    <li class=""><a
                            href="http://miljko.org/index11.html">11</a></li>
                    <li class=""><a
                            href="http://miljko.org/index12.html">12</a></li>
                    <li class=""><a
                            href="http://miljko.org/index13.html">13</a></li>
                    <li class=""><a
                            href="http://miljko.org/index14.html">14</a></li>
                    <li class=""><a
                            href="http://miljko.org/index15.html">15</a></li>
                    <li class=""><a
                            href="http://miljko.org/index16.html">16</a></li>
                <li class="next"><a
                        href="http://miljko.org/index9.html">&raquo;</a></li>
        </ul>
        </div>
    </div>
</div>
<footer>
   <div class="container">
      <hr>
       <div class="row">
        <div class="col-xs-12" id="aboutme">
<p>
    <strong>About Miloš Miljković</strong><br/>
    <p>Hematologist/medical oncologist caring for patients with T-cell malignancies and relapsed solid tumors at the <a href="http://cancer.gov">National Cancer Institute</a> in Bethesda, Maryland.<p><a href="https://twitter.com/miljko">@miljko</a> on Twitter.
</p>        </div>
       </div>
      <hr>
      <div class="row">
         <div class="col-xs-10">&copy; 2018 Miloš Miljković
            &middot; Powered by <a href="http://docs.getpelican.com/" target="_blank">Pelican</a>,
            <a href="http://getbootstrap.com" target="_blank">Bootstrap</a>         </div>
         <div class="col-xs-2"><p class="pull-right"><i class="fa fa-arrow-up"></i> <a href="#">Top</a></p></div>
      </div>
   </div>
</footer>
<script src="http://miljko.org/theme/js/jquery.min.js"></script>

<!-- Include all compiled plugins (below), or include individual files as needed -->
<script src="http://miljko.org/theme/js/bootstrap.min.js"></script>

<!-- Enable responsive features in IE8 with Respond.js (https://github.com/scottjehl/Respond) -->
<script src="http://miljko.org/theme/js/respond.min.js"></script>

</body>
</html>